
**PROFIT GUIDANCE FOR THE GROUP'S UNAUDITED FINANCIAL RESULTS
FOR FIRST QUARTER ENDED 31 MARCH 2019**

The Board of Directors (the “**Board**”) of Pharmesis International Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) wishes to announce that after preliminary assessment of the Group’s unaudited financial results, the Board would like to inform the shareholders and investors that the Group is expected to report a net loss for the unaudited financial results for the first quarter ended 31 March 2019 (“**1QFY19**”) as compared to a net profit for the corresponding period for the first quarter ended 31 March 2018 (“**1QFY18**”).

The expected net loss was mainly attributed to absence of other income and lower revenue in 1QFY19 as compared to 1QFY18.

Further details of the Group’s financial performance will be disclosed when the Company announces its unaudited financial results for 1QFY19.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

BY ORDER OF THE BOARD

Wu Xuedan
Executive Director and Chief Executive Officer
8 May 2019